3 citations
,
July 2015 in “European Journal of Dermatology” This abstract discusses the role of advanced glycation end-products in aging-related skin damage, but does not provide new findings on their impact on alopecia.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
6 citations
,
November 2022 in “Journal of autoimmunity” This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.
277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.